Form SC 13G - Statement of Beneficial Ownership by Certain Investors
23 Octobre 2024 - 12:49AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
CAMP4 Therapeutics Corporation
(Name of Issuer)
Common stock, $0.0001 par value per share
(Title of Class
of Securities)
13463J101
(CUSIP Number)
October 15, 2024
(Date of Event Which
Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
|
¨ |
Rule 13d-1(b) |
|
|
|
|
x |
Rule 13d-1(c) |
|
|
|
|
¨ |
Rule 13d-1(d) |
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information
which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall
not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise
subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 13463J101 |
1. |
Names of Reporting Persons
Northpond Ventures, LP |
2. |
Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
¨ (b) x (1) |
3. |
SEC Use Only |
4. |
Citizenship or Place of Organization
Delaware |
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
5. |
Sole Voting Power
0 |
6. |
Shared Voting Power
471,415 (2) |
7. |
Sole Dispositive Power
0 |
8. |
Shared Dispositive Power
471,415 (2) |
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person
471,415
(2) |
10. |
Check
if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ |
11. |
Percent of Class Represented by Amount in Row (9)
2.4% (3) |
12. |
Type of Reporting Person (See Instructions)
PN |
|
|
|
|
(1) | This Schedule 13G is filed by Northpond Ventures, LP (“Northpond Fund I”), Northpond Ventures
GP, LLC (“Northpond GP”), Northpond Ventures II, LP (“Northpond Fund II”), Northpond Ventures II GP, LLC (“Northpond
II GP”), Northpond Ventures III, LP (“Northpond Fund III”), Northpond Ventures III GP, LLC (“Northpond III GP”),
and Michael P. Rubin (“Rubin” and, with Northpond Fund I, Northpond GP, Northpond Fund II, Northpond II GP, Northpond Fund
III and Northpond III GP, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group”
for purposes of this Schedule 13G. |
| |
(2) | The shares are held by Northpond Fund I. Northpond GP is the general partner of Northpond Fund I and Rubin
is the managing member of Northpond GP. As such, Northpond GP and Rubin have shared dispositive and voting power over the shares held
by Northpond Fund I and may be deemed to have indirect beneficial ownership of the shares held by Northpond Fund I. |
| |
(3) | This percentage is calculated on 19,505,119 shares of Common Stock outstanding as of October 15, 2024
upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus filed with the Securities
and Exchange Commission (the “SEC”) on October 11, 2024. |
CUSIP No. 13463J101 |
1. |
Names of Reporting Persons
Northpond Ventures GP, LLC |
2. |
Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
¨ (b) x (1) |
3. |
SEC Use Only |
4. |
Citizenship or Place of Organization
Delaware |
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
5. |
Sole Voting Power
0 |
6. |
Shared Voting Power
471,415 (2) |
7. |
Sole Dispositive Power
0 |
8. |
Shared Dispositive Power
471,415 (2) |
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person
471,415
(2) |
10. |
Check
if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ |
11. |
Percent of Class Represented by Amount in Row (9)
2.4% (3) |
12. |
Type of Reporting Person (See Instructions)
OO |
|
|
|
|
(1) | This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as
a “group” for purposes of this Schedule 13G. |
| |
(2) | The shares are held by Northpond Fund I. Northpond GP is the general partner of Northpond Fund I and Rubin
is the managing member of Northpond GP. As such, Northpond GP and Rubin have shared dispositive and voting power over the shares held
by Northpond Fund I and may be deemed to have indirect beneficial ownership of the shares held by Northpond Fund I. |
| |
(3) | This percentage is calculated on 19,505,119 shares of Common Stock outstanding as of October 15, 2024
upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus filed with the SEC on October
11, 2024. |
CUSIP No. 13463J101 |
1. |
Names of Reporting Persons
Northpond Ventures II, LP |
2. |
Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
¨ (b) x (1) |
3. |
SEC Use Only |
4. |
Citizenship or Place of Organization
Delaware |
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
5. |
Sole Voting Power
0 |
6. |
Shared Voting Power
1,003,193 (2) |
7. |
Sole Dispositive Power
0 |
8. |
Shared Dispositive Power
1,003,193 (2) |
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person
1,003,193 (2) |
10. |
Check
if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ |
11. |
Percent of Class Represented by Amount in Row (9)
5.1% (3) |
12. |
Type of Reporting Person (See Instructions)
PN |
|
|
|
|
(1) | This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as
a “group” for purposes of this Schedule 13G. |
| |
(2) | The shares are held by Northpond Fund II. Northpond II GP is the general partner of Northpond Fund II
and Rubin is the managing member of Northpond II GP. As such, Northpond II GP and Rubin have shared dispositive and voting power over
the shares held by Northpond Fund II and may be deemed to have indirect beneficial ownership of the shares held by Northpond Fund II. |
| |
(3) | This percentage is calculated on 19,505,119 shares of Common Stock outstanding as of October 15, 2024
upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus filed with the SEC on October
11, 2024. |
CUSIP No. 13463J101 |
1. |
Names of Reporting Persons
Northpond Ventures II GP, LLC |
2. |
Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
¨ (b) x (1) |
3. |
SEC Use Only |
4. |
Citizenship or Place of Organization
Delaware |
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
5. |
Sole Voting Power
0 |
6. |
Shared Voting Power
1,003,193 (2) |
7. |
Sole Dispositive Power
0 |
8. |
Shared Dispositive Power
1,003,193 (2) |
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person
1,003,193 (2) |
10. |
Check
if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ |
11. |
Percent of Class Represented by Amount in Row (9)
5.1% (3) |
12. |
Type of Reporting Person (See Instructions)
OO |
|
|
|
|
(1) | This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as
a “group” for purposes of this Schedule 13G. |
| |
(2) | The shares are held by Northpond Fund II. Northpond II GP is the general partner of Northpond Fund II
and Rubin is the managing member of Northpond II GP. As such, Northpond II GP and Rubin have shared dispositive and voting power over
the shares held by Northpond Fund II and may be deemed to have indirect beneficial ownership of the shares held by Northpond Fund II. |
| |
(3) | This percentage is calculated on 19,505,119 shares of Common Stock outstanding as of October 15, 2024
upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus filed with the SEC on October
11, 2024. |
CUSIP No. 13463J101 |
1. |
Names of Reporting Persons
Northpond Ventures III, LP |
2. |
Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
¨ (b) x (1) |
3. |
SEC Use Only |
4. |
Citizenship or Place of Organization
Delaware |
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
5. |
Sole Voting Power
0 |
6. |
Shared Voting Power
763,636 (2) |
7. |
Sole Dispositive Power
0 |
8. |
Shared Dispositive Power
763,636 (2) |
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person
763,636 (2) |
10. |
Check
if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ |
11. |
Percent of Class Represented by Amount in Row (9)
3.9% (3) |
12. |
Type of Reporting Person (See Instructions)
PN |
|
|
|
|
(1) | This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as
a “group” for purposes of this Schedule 13G. |
| |
(2) | The shares are held by Northpond Fund III. Northpond III GP is the general partner of Northpond Fund III
and Rubin is the managing member of Northpond III GP. As such, Northpond III GP and Rubin have shared dispositive and voting power over
the shares held by Northpond Fund III and may be deemed to have indirect beneficial ownership of the shares held by Northpond Fund III. |
| |
(3) | This percentage is calculated on 19,505,119 shares of Common Stock outstanding as of October 15, 2024
upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus filed with the SEC on October
11, 2024. |
CUSIP No. 13463J101 |
1. |
Names of Reporting Persons
Northpond Ventures III GP, LLC |
2. |
Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
¨ (b) x (1) |
3. |
SEC Use Only |
4. |
Citizenship or Place of Organization
Delaware |
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
5. |
Sole Voting Power
0 |
6. |
Shared Voting Power
763,636 (2) |
7. |
Sole Dispositive Power
0 |
8. |
Shared Dispositive Power
763,636 (2) |
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person
763,636 (2) |
10. |
Check
if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ |
11. |
Percent of Class Represented by Amount in Row (9)
3.9% (3) |
12. |
Type of Reporting Person (See Instructions)
OO |
|
|
|
|
(1) | This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as
a “group” for purposes of this Schedule 13G. |
| |
(2) | The shares are held by Northpond Fund III. Northpond III GP is the general partner of Northpond Fund III
and Rubin is the managing member of Northpond III GP. As such, Northpond III GP and Rubin have shared dispositive and voting power over
the shares held by Northpond Fund III and may be deemed to have indirect beneficial ownership of the shares held by Northpond Fund III. |
| |
(3) | This percentage is calculated on 19,505,119 shares of Common Stock outstanding as of October 15, 2024
upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus filed with the SEC on October
11, 2024. |
CUSIP No. 13463J101 |
1. |
Names of Reporting Persons
Michael P. Rubin |
2. |
Check the Appropriate Box if a Member of a Group (See Instructions)
(a)
¨ (b) x (1) |
3. |
SEC Use Only |
4. |
Citizenship or Place of Organization
United States |
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With |
5. |
Sole Voting Power
0 |
6. |
Shared Voting Power
2,238,244 (2) |
7. |
Sole Dispositive Power
0 |
8. |
Shared Dispositive Power
2,238,244 (2) |
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person
2,238,244 (2) |
10. |
Check
if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ |
11. |
Percent of Class Represented by Amount in Row (9)
11.5% (3) |
12. |
Type of Reporting Person (See Instructions)
IN |
|
|
|
|
(1) | This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as
a “group” for purposes of this Schedule 13G. |
| |
(2) | Consists of (i) 471,415 shares held by Northpond Fund I, (ii) 1,003,193 shares held by Northpond Fund
II, and (iii) 763,636 shares held by Northpond Fund III. Northpond GP is the general partner of Northpond Fund I, Northpond II GP is the
general partner of Northpond Fund II, and Northpond III GP is the general partner of Northpond Fund III. Rubin is the managing member
of each of Northpond GP, Northpond II GP and Northpond III GP and shares voting and investment authority over these shares. |
| |
(3) | This percentage is calculated on 19,505,119 shares of Common Stock outstanding as of October 15, 2024
upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s prospectus filed with the SEC on October
11, 2024. |
Item 1. |
|
|
(a) |
Name of Issuer
CAMP4 Therapeutics Corporation |
|
(b) |
Address of Issuer’s Principal Executive Offices
One Kendall
Square, Building 1400 West, 3rd Floor, Cambridge, MA 02139 |
|
Item 2. |
|
|
(a) |
Name of Person Filing
Northpond Ventures, LP (“Northpond Fund I”)
Northpond Ventures GP, LLC (“Northpond GP”)
Northpond Ventures II, LP (“Northpond Fund II”)
Northpond Ventures II GP, LLC (“Northpond II GP”)
Northpond Ventures III, LP (“Northpond Fund III”)
Northpond Ventures III GP, LLC (“Northpond III GP”)
Michael P. Rubin (“Rubin”) |
|
(b) |
Address of Principal Business Office or, if none, Residence
7500 Old Georgetown Road, Suite 800
Bethesda , MD 20814 |
|
(c) |
Citizenship |
|
Entities: |
Northpond Fund I |
- |
Delaware |
|
|
Northpond GP |
- |
Delaware |
|
|
Northpond Fund II |
- |
Delaware |
|
|
Northpond II GP |
- |
Delaware |
|
|
Northpond Fund III |
- |
Delaware |
|
|
Northpond III GP |
- |
Delaware |
|
Individuals: |
Rubin |
- |
United States |
|
(d) |
Title of Class of Securities
Common Stock, $0.0001 par value (“Common
Stock”) |
|
(e) |
CUSIP Number
13463J101 |
|
Item 3. |
If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
|
|
|
Not applicable |
Item 4. |
Ownership |
|
|
The following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1 is provided as of October 22, 2024: |
Reporting Persons | |
Shares Held Directly | | |
Sole Voting Power | | |
Shared Voting Power | | |
Sole Dispositive Power | | |
Shared Dispositive Power | | |
Beneficial Ownership | | |
Percentage of Class (4) | |
Northpond Fund I (1) | |
| 471,415 | | |
| | | |
| 471,415 | | |
| | | |
| 471,415 | | |
| 471,415 | | |
| 2.4 | % |
Northpond GP (1) | |
| | | |
| | | |
| 471,415 | | |
| | | |
| 471,415 | | |
| 471,415 | | |
| 2.4 | % |
Northpond Fund II (2) | |
| 1,003,193 | | |
| | | |
| 1,003,193 | | |
| | | |
| 1,003,193 | | |
| 1,003,193 | | |
| 5.1 | % |
Northpond II GP (2) | |
| | | |
| | | |
| 1,003,193 | | |
| | | |
| 1,003,193 | | |
| 1,003,193 | | |
| 5.1 | % |
Northpond Fund III (3) | |
| 763,636 | | |
| | | |
| 763,636 | | |
| | | |
| 763,636 | | |
| 763,636 | | |
| 3.9 | % |
Northpond III GP (3) | |
| | | |
| | | |
| 763,636 | | |
| | | |
| 763,636 | | |
| 763,636 | | |
| 3.9 | % |
Rubin (1) (2) | |
| | | |
| | | |
| 2,238,244 | | |
| | | |
| 2,238,244 | | |
| 2,238,244 | | |
| 11.5 | % |
|
(1) | Includes 471,415 shares held by Northpond Fund I. Northpond
GP is the general partner of Northpond Fund I and Rubin is the managing member of Northpond GP. As such, Northpond GP and Rubin have
shared dispositive and voting power over the shares held by Northpond Fund I and may be deemed to have indirect beneficial ownership
of the shares held by Northpond Fund I. |
|
(2) | Includes 1,003,193 shares held by Northpond Fund II. Northpond
II GP is the general partner of Northpond Fund II and Rubin is the managing member of Northpond II GP. As such, Northpond II GP and Rubin
have shared dispositive and voting power over the shares held by Northpond Fund II and may be deemed to have indirect beneficial ownership
of the shares held by Northpond Fund II. |
|
(3) | Includes 763,636 shares held by Northpond Fund III. Northpond
III GP is the general partner of Northpond Fund III and Rubin is the managing member of Northpond III GP. As such, Northpond III GP and
Rubin have shared dispositive and voting power over the shares held by Northpond Fund III and may be deemed to have indirect beneficial
ownership of the shares held by Northpond Fund III. |
|
(4) | This percentage is calculated on 19,505,119 shares of Common
Stock outstanding as of October 15, 2024 upon the closing of the Issuer’s initial public offering, as reported in the Issuer’s
prospectus filed with the SEC on October 11, 2024. |
Item 5. |
Ownership of Five Percent or Less of a Class |
|
|
|
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨ |
|
|
Item 6. |
Ownership of More than Five Percent on Behalf of Another Person |
|
|
|
Not applicable |
|
|
Item 7. |
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person |
|
|
|
Not applicable |
|
|
Item 8. |
Identification and Classification of Members of the Group |
|
|
|
Not applicable |
Item 9. |
Notice of Dissolution of Group |
|
|
|
Not applicable |
|
Item 10. |
Certification |
|
|
|
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect. |
Signature
After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true, complete and correct.
Dated: October 22, 2024
Northpond Ventures, LP |
|
|
|
By: |
Northpond Ventures GP, LLC |
|
its |
General Partner |
|
|
|
By: |
/s/ Patrick Smerkers |
|
|
Name: Patrick Smerkers |
|
|
Title: Authorized Signatory |
|
|
|
Northpond Ventures GP, LLC |
|
|
|
By: |
/s/ Patrick Smerkers |
|
|
Name: Patrick Smerkers |
|
|
Title: Authorized Signatory |
|
|
|
Northpond Ventures II, LP |
|
|
|
By: |
Northpond Ventures II GP, LLC |
|
its |
General Partner |
|
|
|
By: |
/s/ Patrick Smerkers |
|
|
Name: Patrick Smerkers |
|
|
Title: Authorized Signatory |
|
|
|
Northpond Ventures II GP, LLC |
|
|
|
By: |
/s/ Patrick Smerkers |
|
|
Name: Patrick Smerkers |
|
|
Title: Authorized Signatory |
|
|
|
Northpond Ventures III, LP |
|
|
|
By: |
Northpond Ventures III GP, LLC |
|
its |
General Partner |
|
|
|
By: |
/s/ Patrick Smerkers |
|
|
Name: Patrick Smerkers |
|
|
Title: Authorized Signatory |
|
|
|
Northpond Ventures III GP, LLC |
|
|
|
By: |
/s/ Patrick Smerkers |
|
|
Name: Patrick Smerkers |
|
|
Title: Authorized Signatory |
|
|
|
/s/ Michael P. Rubin |
|
Michael P. Rubin |
|
|
ATTENTION |
|
Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001). |
Exhibit(s):
EXHIBIT A
JOINT FILING AGREEMENT
We, the undersigned, hereby express our agreement that the attached
Schedule 13G (or any amendments thereto) relating to the Common Stock of CAMP4 Therapeutics Corporation is filed on behalf of each of
us.
Dated: October 22, 2024
Northpond Ventures, LP |
|
|
|
By: |
Northpond Ventures GP, LLC |
|
its |
General Partner |
|
|
|
By: |
/s/ Patrick Smerkers |
|
|
Name: Patrick Smerkers |
|
|
Title: Authorized Signatory |
|
|
|
Northpond Ventures GP, LLC |
|
|
|
By: |
/s/ Patrick Smerkers |
|
|
Name: Patrick Smerkers |
|
|
Title: Authorized Signatory |
|
|
|
Northpond Ventures II, LP |
|
|
|
By: |
Northpond Ventures II GP, LLC |
|
its |
General Partner |
|
|
|
By: |
/s/ Patrick Smerkers |
|
|
Name: Patrick Smerkers |
|
|
Title: Authorized Signatory |
|
|
|
Northpond Ventures II GP, LLC |
|
|
|
By: |
/s/ Patrick Smerkers |
|
|
Name: Patrick Smerkers |
|
|
Title: Authorized Signatory |
|
|
|
Northpond Ventures III, LP |
|
|
|
By: |
Northpond Ventures III GP, LLC |
|
its |
General Partner |
|
|
|
By: |
/s/ Patrick Smerkers |
|
|
Name: Patrick Smerkers |
|
|
Title: Authorized Signatory |
|
|
|
Northpond Ventures III GP, LLC |
|
|
|
By: |
/s/ Patrick Smerkers |
|
|
Name: Patrick Smerkers |
|
|
Title: Authorized Signatory |
|
|
|
/s/ Michael P. Rubin |
|
Michael P. Rubin |
|
CAMP4 Therapeutics (NASDAQ:CAMP)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
CAMP4 Therapeutics (NASDAQ:CAMP)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024